Compare UDMY & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UDMY | BIOA |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 716.5M | 681.9M |
| IPO Year | 2021 | N/A |
| Metric | UDMY | BIOA |
|---|---|---|
| Price | $4.63 | $16.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $9.29 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 1.6M | 371.2K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $789,844,000.00 | N/A |
| Revenue This Year | $4.12 | $720.93 |
| Revenue Next Year | $4.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.42 | N/A |
| 52 Week Low | $4.02 | $4.07 |
| 52 Week High | $8.09 | $24.00 |
| Indicator | UDMY | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 46.53 |
| Support Level | $4.23 | $15.49 |
| Resistance Level | $5.20 | $18.26 |
| Average True Range (ATR) | 0.30 | 0.91 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 46.77 | 38.17 |
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Enterprise segment and Consumer segment, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America, and also has its presence in Europe, Middle East, Africa; Asia Pacific; and Latin America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.